JP6768522B2 - Ｈｉｖ治療におけるアポトーシスタンパク質阻害剤（ｉａｐ）のアンタゴニストの使用 - Google Patents

Ｈｉｖ治療におけるアポトーシスタンパク質阻害剤（ｉａｐ）のアンタゴニストの使用 Download PDF

Info

Publication number
JP6768522B2
JP6768522B2 JP2016570242A JP2016570242A JP6768522B2 JP 6768522 B2 JP6768522 B2 JP 6768522B2 JP 2016570242 A JP2016570242 A JP 2016570242A JP 2016570242 A JP2016570242 A JP 2016570242A JP 6768522 B2 JP6768522 B2 JP 6768522B2
Authority
JP
Japan
Prior art keywords
substituted
alkyl
unsubstituted
formula
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016570242A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017522273A5 (enExample
JP2017522273A (ja
Inventor
パシュ，ラーズ
チャンダ，サミット，ケイ．
バモス，ミッチェル，デニス
デビッド，ピーター コスフォード，ニコラス
デビッド，ピーター コスフォード，ニコラス
テリエテ，ピーター
マーレット，ジョン
ディアズ，アルトゥーロ
ヤング，ジョン，エー．ティー．
Original Assignee
サンフォード−バーンハム メディカル リサーチ インスティテュート
サンフォード−バーンハム メディカル リサーチ インスティテュート
ソーク インスティテュート フォー バイオロジカル スタディーズ
ソーク インスティテュート フォー バイオロジカル スタディーズ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サンフォード−バーンハム メディカル リサーチ インスティテュート, サンフォード−バーンハム メディカル リサーチ インスティテュート, ソーク インスティテュート フォー バイオロジカル スタディーズ, ソーク インスティテュート フォー バイオロジカル スタディーズ filed Critical サンフォード−バーンハム メディカル リサーチ インスティテュート
Publication of JP2017522273A publication Critical patent/JP2017522273A/ja
Publication of JP2017522273A5 publication Critical patent/JP2017522273A5/ja
Application granted granted Critical
Publication of JP6768522B2 publication Critical patent/JP6768522B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2016570242A 2014-06-04 2015-06-04 Ｈｉｖ治療におけるアポトーシスタンパク質阻害剤（ｉａｐ）のアンタゴニストの使用 Active JP6768522B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462007702P 2014-06-04 2014-06-04
US62/007,702 2014-06-04
PCT/US2015/034281 WO2015187998A2 (en) 2014-06-04 2015-06-04 Use of inhibitor of apoptosis protein (iap) antagonists in hiv therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020066803A Division JP2020125302A (ja) 2014-06-04 2020-04-02 Ｈｉｖ治療におけるアポトーシスタンパク質阻害剤（ｉａｐ）のアンタゴニストの使用

Publications (3)

Publication Number Publication Date
JP2017522273A JP2017522273A (ja) 2017-08-10
JP2017522273A5 JP2017522273A5 (enExample) 2018-07-12
JP6768522B2 true JP6768522B2 (ja) 2020-10-14

Family

ID=54767596

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016570242A Active JP6768522B2 (ja) 2014-06-04 2015-06-04 Ｈｉｖ治療におけるアポトーシスタンパク質阻害剤（ｉａｐ）のアンタゴニストの使用
JP2020066803A Pending JP2020125302A (ja) 2014-06-04 2020-04-02 Ｈｉｖ治療におけるアポトーシスタンパク質阻害剤（ｉａｐ）のアンタゴニストの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020066803A Pending JP2020125302A (ja) 2014-06-04 2020-04-02 Ｈｉｖ治療におけるアポトーシスタンパク質阻害剤（ｉａｐ）のアンタゴニストの使用

Country Status (5)

Country Link
US (2) US10300074B2 (enExample)
EP (1) EP3151920B1 (enExample)
JP (2) JP6768522B2 (enExample)
CA (1) CA2950911C (enExample)
WO (1) WO2015187998A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6382831B2 (ja) 2012-11-30 2018-08-29 サンフォード−バーンハム メディカル リサーチ インスティテュート アポトーシス阻害タンパク質（ｉａｐ）のアンタゴニスト
EP3013329B1 (en) * 2013-06-25 2020-08-05 The Walter and Eliza Hall Institute of Medical Research Smac mimetics for the treatment of persistent intracellular hbv infection
US10441654B2 (en) 2014-01-24 2019-10-15 Children's Hospital Of Eastern Ontario Research Institute Inc. SMC combination therapy for the treatment of cancer
CA2950911C (en) 2014-06-04 2023-10-10 Sanford-Burnham Medical Research Institute Use of inhibitor of apoptosis protein (iap) antagonists in hiv therapy
CN118436801A (zh) 2016-05-20 2024-08-06 豪夫迈·罗氏有限公司 Protac抗体缀合物及其使用方法
CN113453678A (zh) * 2018-11-26 2021-09-28 德彪药业国际股份公司 Hiv感染的联合治疗
EP4342473A3 (en) * 2018-11-30 2024-05-15 GlaxoSmithKline Intellectual Property Development Limited Compounds useful in hiv therapy
US10870663B2 (en) 2018-11-30 2020-12-22 Glaxosmithkline Intellectual Property Development Limited Compounds useful in HIV therapy
CN110028508B (zh) * 2019-05-16 2021-05-28 南京华威医药科技集团有限公司 一种抗肿瘤的重氮双环类细胞凋亡蛋白抑制剂
EP4010081A4 (en) 2019-08-08 2023-07-26 Institute For Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center POLYTHERAPY FOR THE TREATMENT OF CANCER
JP7273173B2 (ja) * 2019-09-26 2023-05-12 富士フイルム株式会社 皮膚感作性測定試薬、皮膚感作性の測定方法、及び化合物
US20230115837A1 (en) * 2019-11-08 2023-04-13 Sanford Burnham Prebys Medical Discovery Institute Inhibitor of apoptosis (iap) protein antagonists
US20230295181A1 (en) * 2020-04-30 2023-09-21 Sanford Burnham Prebys Medical Discovery Institute Inhibitor of apoptosis (iap) protein antagonists
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
AR131299A1 (es) 2022-12-09 2025-03-05 Debiopharm Int Sa Nuevos inhibidores de iap, métodos para fabricarlos y usos de los mismos
EP4712960A2 (en) * 2023-05-15 2026-03-25 Recludix Pharma, Inc. Stat degraders and uses thereof

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5455242A (en) 1991-09-27 1995-10-03 Merrell Dow Pharmaceuticals Inc. Carboxyalkyl tricyclic derivatives useful as inhibitors of enkephalinase and ace
US5457196A (en) 1991-09-27 1995-10-10 Merrell Dow Pharmaceuticals Inc. 2-substituted indane-2-carboxyalkyl derivatives useful as inhibitors of enkephalinase and ACE
CA2146238C (en) 1992-10-30 2001-03-13 Gary A. Flynn Novel mercaptoacetylamide bicyclic lactam derivatives useful as inhibitors of enkephalinase and ace
US5508272A (en) 1993-06-15 1996-04-16 Bristol-Myers Squibb Company Compounds containing a fused bicycle ring and processes therefor
EP1578777B1 (en) 2002-07-15 2008-11-26 The Trustees of Princeton University Iap binding compounds
US7932382B2 (en) 2004-01-16 2011-04-26 The Regents Of The University Of Michigan Conformationally constrained Smac mimetics and the uses thereof
US7309792B2 (en) 2004-03-01 2007-12-18 Board Of Regents, The University Of Texas System Dimeric small molecule potentiators of apoptosis
AU2005228950B2 (en) 2004-03-23 2012-02-02 Genentech, Inc. Azabicyclo-octane inhibitors of IAP
RS52545B (sr) 2004-04-07 2013-04-30 Novartis Ag Inhibitori protein apoptoze (iap)
NZ588799A (en) 2004-07-02 2012-06-29 Genentech Inc Inhibitors of iap
WO2006010118A2 (en) 2004-07-09 2006-01-26 The Regents Of The University Of Michigan Conformationally constrained smac mimetics and the uses thereof
EP2457895A1 (en) 2004-07-12 2012-05-30 Idun Pharmaceuticals, Inc. Tetrapeptide analogs
ES2475207T3 (es) 2004-07-15 2014-07-10 Tetralogic Pharmaceuticals Corporation Compuestos de unión a IAP
DK1836201T4 (da) 2004-12-20 2013-11-11 Genentech Inc Pyrrolidininhibitorer af IAP.
PL1851200T3 (pl) 2005-02-25 2014-06-30 Tetralogic Pharm Corp Dimeryczne inhibitory IAP
KR20080022092A (ko) 2005-06-08 2008-03-10 노파르티스 아게 유기 화합물
WO2007041775A1 (en) * 2005-10-10 2007-04-19 The University Of Queensland Cysteine protease inhibitors incorporating azide groups
KR20080067357A (ko) 2005-10-25 2008-07-18 에게라 쎄라퓨틱스 인코포레이티드 Ｉａｐ ｂｉｒ 도메인 결합 화합물
WO2007101347A1 (en) 2006-03-07 2007-09-13 Aegera Therapeutics Inc. Bir domain binding compounds
CN101484151B (zh) 2006-05-05 2012-11-21 密执安州立大学董事会 二价smac模拟物及其应用
US8048886B2 (en) 2006-12-07 2011-11-01 Novartis Ag Substituted pyrazine-3-one-derivatives as IAP inhibitors
US20090010941A1 (en) * 2007-04-09 2009-01-08 University Of Massachusetts Methods for treating HIV
EP2079309B1 (en) 2007-04-12 2015-11-11 Joyant Pharmaceuticals Inc SMAC MIMEE DIMERS AND TRIMERS USEFUL AS ANTICANCER AGENTS
EP2139490B1 (en) * 2007-04-13 2014-07-02 The Regents of the University of Michigan Diazo bicyclic smac mimetics and the uses thereof
TWI432212B (zh) 2007-04-30 2014-04-01 Genentech Inc Ｉａｐ抑制劑
EP2058312A1 (en) 2007-11-09 2009-05-13 Universita' degli Studi di Milano SMAC mimetic compounds as apoptosis inducers
US8445473B2 (en) 2008-04-11 2013-05-21 The Regents Of The University Of Michigan Heteroaryl-substituted bicyclic Smac mimetics and the uses thereof
US20110269244A1 (en) * 2009-12-30 2011-11-03 Petter Russell C Ligand-directed covalent modification of protein
RS54123B1 (sr) * 2010-01-27 2015-12-31 Viiv Healthcare Company Terapeutska kombinacija koja sadrži dolutegravir, abacavir i lamivudine
WO2012125622A1 (en) 2011-03-14 2012-09-20 Bristol-Myers Squibb Company Substituted adipic acid amides and uses thereof
US20150174235A1 (en) * 2012-06-06 2015-06-25 Bionor Immuno As Vaccine
JP6382831B2 (ja) 2012-11-30 2018-08-29 サンフォード−バーンハム メディカル リサーチ インスティテュート アポトーシス阻害タンパク質（ｉａｐ）のアンタゴニスト
CA2950911C (en) 2014-06-04 2023-10-10 Sanford-Burnham Medical Research Institute Use of inhibitor of apoptosis protein (iap) antagonists in hiv therapy

Also Published As

Publication number Publication date
WO2015187998A3 (en) 2016-02-04
EP3151920A4 (en) 2017-12-27
CA2950911A1 (en) 2015-12-10
US10300074B2 (en) 2019-05-28
US20170196879A1 (en) 2017-07-13
EP3151920A2 (en) 2017-04-12
EP3151920B1 (en) 2025-08-06
CA2950911C (en) 2023-10-10
US10864217B2 (en) 2020-12-15
JP2020125302A (ja) 2020-08-20
US20200121693A1 (en) 2020-04-23
WO2015187998A2 (en) 2015-12-10
JP2017522273A (ja) 2017-08-10

Similar Documents

Publication Publication Date Title
JP6768522B2 (ja) Ｈｉｖ治療におけるアポトーシスタンパク質阻害剤（ｉａｐ）のアンタゴニストの使用
CN107257800B (zh) 通过双功能分子诱导靶蛋白降解的方法
JP5385268B2 (ja) インドリン−２−オンおよびアザ−インドリン−２−オン
US10150780B2 (en) Spirocyclic heterocycle compounds useful as HIV integrase inhibitors
KR20250020690A (ko) 세레블론(crbn)에 대한 리간드
RS60658B1 (sr) Inhibitori lizin specifične demetilaze-1
WO2019170150A1 (zh) 蛋白降解靶向bcr-abl化合物及其抗肿瘤应用
US20240317758A1 (en) Nek7 inhibitors
US20180028534A1 (en) Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
JP2019038848A (ja) 白血病を予防および治療するためのマレイミド誘導体の使用
TW200409775A (en) Novel pyrazolopyridines as cyclin dependent kinase inhibitors
US8669255B2 (en) Substituted octahydropyrrolo[1,2-a]pyrazines as calcium channel blockers
EP3941457B1 (en) Inhibitors of histone deacetylase useful for the treatment or prevention of hiv infection
EP3807296A1 (en) Peptidomimetic inhibitors of the peptidyl-prolyl cis/trans isomerase (pin1)
US12365674B2 (en) Inhibitors of histone deacetylase useful for the treatment or prevention of HIV infection
CN117597346A (zh) Nek7抑制剂
US10689381B2 (en) Vinblastine 20″ amides: synthetic analogs that maintain or improve potency and simultaneously overcome Pgp-derived efflux and resistance
WO2026050773A1 (en) Protein kinase inhibitors and uses thereof
WO2024186579A1 (en) Protein kinase inhibitors and uses thereof
WO2025255442A1 (en) Trim21-targeted compounds and uses thereof
EA046667B1 (ru) ПИРРОЛО[2,3-b]ПИРАЗИНЫ В КАЧЕСТВЕ ИНГИБИТОРА HPK1 И ИХ ПРИМЕНЕНИЕ
HK40029219B (en) Compounds as neurokinin-1 receptor antagonists and uses thereof
HK40034417A (en) Macrocyclic compounds as trk kinases inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180601

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180601

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190520

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190819

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20191209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200402

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20200402

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20200415

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20200513

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20200518

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200601

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200826

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200907

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200923

R150 Certificate of patent or registration of utility model

Ref document number: 6768522

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250